Whitepaper

MEA to probe ALS phenotypes in neuronal disease models

Carrie Haslam Carrie Haslam
6 Feb 2024 0 min read

Login or Register

After logging in, you can access the full content

Author

Read Bio
Carrie Haslam
Author

Early-stage ALS drug discovery workflows can be challenging due to a lack of access to consistent, physiologically relevant human cell models. In this app note, discover a functional iPSC-derived neuronal model of ALS from bit.bio. Also, explore an MEA workflow featuring the Axion Maestro Pro that was used to validate this model’s reduced neuronal activity and network formation compared to a genetically matched control, highlighting its physiological relevance for pre-clinical ALS research.

Related Whitepapers

Clinical Trials
Drugs and Therapies
Machine learning
Research and Development
Tools and techniques
+4
05 August 2025

Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams ...

Carrie Haslam Carrie Haslam
Aug 5, 2025 • 1 min read
CRISPR
Drugs and Therapies
Genomics
Research and Development
Tools & Techniques
Tools and techniques
+5
08 May 2025

App Note: High-Throughput Single-Cell Genome Profiling

See how the new Shasta™ Single Cell System enabled high-throughput single-cell DNA-seq library preparation to detect tumor-driving mutations....

Carrie Haslam Carrie Haslam
May 8, 2025 • 1 min read
Clinical Trials
Research and Development
Technology
+2
29 April 2025

Beyond the Lab: Clinical Trials

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug dis...

Carrie Haslam Carrie Haslam
Apr 29, 2025 • 1 min read
Drugs and Therapies
Machine learning
Technology
Tools and techniques
+3
21 March 2025

Beyond the Lab: Artificial Intelligence

Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care....

Carrie Haslam Carrie Haslam
Mar 21, 2025 • 1 min read
Antibodies
Diseases
Research and Development
Tools and techniques
+3
24 October 2024

Beyond the lab: antibodies

Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscien...

Carrie Haslam Carrie Haslam
Oct 24, 2024 • 1 min read
Diseases
Research & Development
Research and Development
RNAs
Tools and techniques
+4
13 June 2024

Beyond the lab: screening

This report provides exclusive access to content on innovative screening methods to improve detection and diagnosis of prevalent conditions like cance...

Carrie Haslam Carrie Haslam
Jun 13, 2024 • 1 min read
Drugs and Therapies
Genomics
Research and Development
Technology
Tools and techniques
+4
10 May 2024

Poster: Assays for DDX3, DDX5, DDX17, RIG-I, and MDA5

A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors....

Carrie Haslam Carrie Haslam
May 10, 2024 • 1 min read
Drugs and Therapies
Genomics
Research and Development
Technology
Tools and techniques
+4
07 May 2024

Poster: Assays for PRMT5, MLL4, METTL3/14, & NSP14

AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14...

Carrie Haslam Carrie Haslam
May 7, 2024 • 1 min read